Regeneron Pharmaceuticals Inc (REGN)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 29,353,600 | 25,973,100 | 22,664,000 | 18,768,800 | 11,025,300 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $29,353,600K
= 0.00
Regeneron Pharmaceuticals Inc's debt-to-equity ratio has exhibited a declining trend over the past five years based on the provided data. As of December 31, 2020, the ratio stood at 0.18, indicating that the company had $0.18 in debt for every $1 of equity. This ratio decreased to 0.11 by December 31, 2021, suggesting a reduction in debt relative to equity. Subsequently, the ratio continued to decline to 0.09 by December 31, 2022, further improving the company's leverage position.
By December 31, 2023, the debt-to-equity ratio fell to 0.08, signaling a sustained trend of efficient capital structure management by Regeneron Pharmaceuticals Inc. The most recent data point as of December 31, 2024, shows the ratio at 0.07, indicating a prudent level of indebtedness compared to shareholder equity.
Overall, the decreasing trend in the debt-to-equity ratio reflects Regeneron Pharmaceuticals Inc's efforts to reduce its reliance on debt financing and strengthen its financial position through enhanced equity contributions. This improving ratio suggests a healthier balance sheet structure and potentially lowers financial risk for the company.
Peer comparison
Dec 31, 2024